Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
Key Highlights
- ➤Allogene presented clinical progress in solid tumors at the SITC Annual Meeting.
- ➤Preclinical DLL3/CD70 dual CAR T candidate targets small cell lung cancer and neuroendocrine tumors.
- ➤Optimized CAR integration improved tumor control in preclinical DLL3/CD70 studies.
- ➤Dagger technology enhanced resistance to immune-mediated rejection when paired with CD70 CAR.
- ➤Allogene is expanding off-the-shelf CAR T development across oncology and autoimmune disease.
Expert Statements
Zachary Roberts, President and Chief Executive Officer of Allogene Therapeutics
“Our presence at SITC underscores the promise of our off-the-shelf CAR T platform, from clinical progress in solid tumors to next-generation innovation informed by learnings across our pipeline.”
Zachary Roberts, President and Chief Executive Officer of Allogene Therapeutics
“We are building on this experience to develop a new generation of cell therapies with the potential to expand patient access, reach more treatment settings and transform care across oncology and autoimmune disease.”
* Two Invited Presentations Showcase Clinical Progress in Solid Tumors and Allogene's Broader Vision in Oncology and Autoimmune Disease * Preclinical Poster Features Next-Generation DLL3/CD70 Dual CAR T Product Candidate for Small Cell Lung Cancer and Other Neuroendocrine Tumors, Demonstrating Continued Innovation with Dagger(®) Technology SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona. The Company’s participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolution of its platform.
“Our presence at SITC underscores the promise of our off-the-shelf CAR T platform, from clinical progress in solid tumors to next-generation innovation informed by learnings across our pipeline,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics. “We are building on this experience to develop a new generation of cell therapies with the potential to expand patient access, reach more treatment settings and transform care across oncology and autoimmune disease.”
Get started
Create a free account to read the full story.